Maria B Bilò1, Markus Ollert2,3, Simon Blank4. 1. Allergy Unit, Department of Internal Medicine, University Hospital of Ancona - Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy. 2. Department of Infection and Immunity, Luxembourg Institute of Health (LIH), Esch-sur-Alzette, Luxembourg. 3. Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis, University of Southern Denmark, Odense, Denmark. 4. Center of Allergy and Environment (ZAUM), Technical University of Munich, School of Medicine, and Helmholtz Center Munich, German Research Center for Environmental Health, Munich, Germany.
Abstract
PURPOSE OF REVIEW: Component-resolved diagnostics (CRD) is a new tool aiming at detecting IgE-mediated sensitizations against individual, relevant allergens. Here, we discuss recent literature on molecular diagnosis in the field of Hymenoptera venom allergy (HVA) as well as CRD strengths and weaknesses. RECENT FINDINGS: CRD, using single molecules or panels of allergens, may discriminate between primary sensitization and cross-reactivity in patients with double/multiple positivity in diagnostic tests with whole extracts, allowing the specialist to choose the most suitable venom for specific immunotherapy (VIT), avoiding unnecessary VIT and reducing the risk of side effects. Future availability of the cross-reactive recombinant pairs of allergens of different species may further increase the diagnostic performance. CRD may be useful in patients with negative allergy tests and a proven history of a previous systemic reaction, including those with mast cell disorders, who could benefit from VIT. In honeybee venom allergy, different sensitization profiles have been identified, which could be associated with a greater risk of VIT failure or treatment side effects. SUMMARY: CRD is undoubtedly an innovative diagnostic method that leads to a more precise definition of the sensitization profile of the HVA patient. Together with a better knowledge of the molecular composition of different venom extracts, CRD may contribute to optimize patient-tailored therapy.
PURPOSE OF REVIEW: Component-resolved diagnostics (CRD) is a new tool aiming at detecting IgE-mediated sensitizations against individual, relevant allergens. Here, we discuss recent literature on molecular diagnosis in the field of Hymenoptera venom allergy (HVA) as well as CRD strengths and weaknesses. RECENT FINDINGS:CRD, using single molecules or panels of allergens, may discriminate between primary sensitization and cross-reactivity in patients with double/multiple positivity in diagnostic tests with whole extracts, allowing the specialist to choose the most suitable venom for specific immunotherapy (VIT), avoiding unnecessary VIT and reducing the risk of side effects. Future availability of the cross-reactive recombinant pairs of allergens of different species may further increase the diagnostic performance. CRD may be useful in patients with negative allergy tests and a proven history of a previous systemic reaction, including those with mast cell disorders, who could benefit from VIT. In honeybee venom allergy, different sensitization profiles have been identified, which could be associated with a greater risk of VIT failure or treatment side effects. SUMMARY:CRD is undoubtedly an innovative diagnostic method that leads to a more precise definition of the sensitization profile of the HVA patient. Together with a better knowledge of the molecular composition of different venom extracts, CRD may contribute to optimize patient-tailored therapy.
Authors: Simon Blank; Murilo Luiz Bazon; Johannes Grosch; Carsten B Schmidt-Weber; Márcia Regina Brochetto-Braga; Maria Beatrice Bilò; Thilo Jakob Journal: Curr Allergy Asthma Rep Date: 2020-07-09 Impact factor: 4.806
Authors: Johannes Grosch; Christiane Hilger; Maria Beatrice Bilò; Stephanie Kler; Maximilian Schiener; Gunnar Dittmar; François Bernardin; Antoine Lesur; Markus Ollert; Carsten B Schmidt-Weber; Simon Blank Journal: Toxins (Basel) Date: 2020-05-14 Impact factor: 4.546
Authors: Johannes Grosch; Antoine Lesur; Stéphanie Kler; François Bernardin; Gunnar Dittmar; Elisabetta Francescato; Simon J Hewings; Constanze A Jakwerth; Ulrich M Zissler; Matthew D Heath; Markus Ollert; Matthias F Kramer; Christiane Hilger; Maria Beatrice Bilò; Carsten B Schmidt-Weber; Simon Blank Journal: Toxins (Basel) Date: 2022-04-15 Impact factor: 5.075
Authors: Martin Feindor; Matthew D Heath; Simon J Hewings; Thalia L Carreno Velazquez; Simon Blank; Johannes Grosch; Thilo Jakob; Peter Schmid-Grendelmeier; Ludger Klimek; David B K Golden; Murray A Skinner; Matthias F Kramer Journal: Toxins (Basel) Date: 2021-09-01 Impact factor: 4.546